Cargando…
Predictors of immunotherapy benefit in Merkel cell carcinoma
Merkel cell carcinoma is a rare cancer for which immune checkpoint blockade is standard-of-care for recurrent/metastatic disease. However, not all patients benefit from immunotherapy. A greater understanding of molecular mechanisms and predictive biomarkers are unmet needs. We retrospectively analyz...
Autores principales: | Kacew, Alec J., Dharaneeswaran, Harita, Starrett, Gabriel J., Thakuria, Manisha, LeBoeuf, Nicole R., Silk, Ann W., DeCaprio, James A., Hanna, Glenn J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720777/ https://www.ncbi.nlm.nih.gov/pubmed/33315984 http://dx.doi.org/10.18632/oncotarget.27823 |
Ejemplares similares
-
Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
por: Hanna, Glenn J., et al.
Publicado: (2020) -
YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma
por: Frost, Thomas C., et al.
Publicado: (2023) -
Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
por: Hanna, Glenn J., et al.
Publicado: (2020) -
Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma
por: Starrett, Gabriel J., et al.
Publicado: (2017) -
Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma
por: Starrett, Gabriel J., et al.
Publicado: (2020)